LifeNome is the world’s premier B2B science-based health and wellness personalization AI platform. Its Genomics AI® engine leverages an individual’s unique biological, physiological, and behavioral/lifestyle data to provide precision health and wellness analytics and hyper-personalized product/service selection and formulation. Brands and retailers can either match their existing products and services to an individual’s needs, or they can formulate/design highly personalized products and services for their customers.
LifeNome’s Genomics AI® engine combines machine learning methodologies with computational genomics and complexes the systems models to assess individual predispositions to over 1,500 health and wellness traits and match thousands of product ingredients and program elements to an individual’s unique biology, physiology, and lifestyle. It is powered by more than 30,000 peer-reviewed studies and has been calibrated with and validated using a dataset of more than 500,000 genotype-phenotype profiles.
LifeNome’s current partnerships include some of the world’s most prominent brands and organizations including Allergan, Unilever, Zurich insurance, IBM, the World Economic Forum, Biologique Recherche, and many others.
LifeNome was founded in March 2016 in New York City, with the mission of bringing rigorous science to the personalization of products and services within the health and wellness sector. The premise of science-based personalization has improved the effectiveness of products and services for addressing an individual’s unique needs while ensuring their data is secure and controlled by their own consent.
Since then LifeNome has developed dozens of products for science-based personalization of retail products, nutrition, supplements, and food products, skincare, haircare, and other beauty products, fitness and dieting programs, and preventative health programs.
A World Class Team: Scientific and AI Thought Leadership
The founding team of LifeNome consists of some of the top scholars in their respective teams.
Ali Mostashari, Ph.D., LifeNome’s CEO, is an MIT Ph.D. with more than 15 years of experience in technology research and development within the industry, academia, and the public sector. He is currently serving as a member of the Global Futures Council for Consumption at the World Economic Forum. Prior to LifeNome, Ali was an Associate Professor and Program Director at the School of Systems and Enterprises at Stevens Institute of Technology, where he directed the institute’s Smart Cities initiative and systems thinking research.
From 2004-2008, Ali served as a LEAD Program Manager and Strategic Resource Manager respectively at the United Nations Development Programme (UNDP) in New York City overseeing a development portfolio of over US$1.2 billion. He is among the top 30 cited scholars in complexity science in the world and has authored multiple books and more than a hundred scientific papers on various aspects of complex systems. Ali has been recognized as an Asia 21 Young Leader, an MIT Sustainability Fellow, and a UNDP Leadership Development Program Finalist.
Raya Khanin, Ph.D., LifeNome’s Chief Science Officer, is in the top 25 cited scholars in computational genomics and has published in prestigious academic journals such as Nature and Cell. She received her Ph.D. from the Weizman Institute and is the recipient of the Dorothy Hudgkin Royal Society Fellowship.
Mario Storga, Ph.D., is LifeNome’s VP of Technology and is in the top 20 cited scholars in semantic networks in the world. He has served as a Professor and Program Head at the University of Zagreb and is a distinguished member of the Design Society.
Rigorous Approach to AI for Better Products
LifeNome’s proprietary Genomics AI® technology has revolutionized predisposition assessment from a linear statistical approach to a polygenic, vector clustering-based classification model which can take into consideration a complex pattern of biological, physiological and behavioral data for risk and predisposition assessments.
This paradigm shift has resulted in significant improvements in the predictive reliability of predisposition risks and combined with one of the most comprehensive and sophisticated gene-chemical interaction analysis engines allows for hyper-personalization of products for individuals.
Genomics AI® provides a significant contribution to the area of personal genomics through the application of a wide range of real-world data validated AI and machine learning approaches. It is because of this rigorous approach to AI and machine learning that the scientific teams of some of the world’s most prominent brands and organizations have opted to leverage LifeNome’s technology in addressing their organization’s personalization needs.
Revolutionary Technology Driving Innovation
LifeNome leverages its revolutionary technology together with its openness to collaboration as one of the strongest drivers of innovation in precision consumption and preventative health and wellness.
Through partnerships with world-class organizations such as IBM, Mount Sinai Healthcare System, and the World Economic Forum, LifeNome is creating a precision consumer marketplace that allows consumers to control their personal biological, biometric, behavioral and lifestyle data while leveraging it to receive highly personalized products and services that are uniquely suited to advance their health and wellbeing. And through its other global partnerships, LifeNome’s technology has served populations in more than a dozen countries in Asia, Latin America, Europe, and North America with personalized health and wellness analytics, products, and services.
Addressing Human Wellness Through Personalization
The disruptive potential of AI in healthcare is unsurpassed by any other recent technological advances made within the health sciences. The availability of unprecedented amounts of data coupled with model-based understandings of human biology holds the promise of highly personalized approaches to address human health and wellness. The next decade will be witness to fundamental changes in the way health is assessed and delivered in a personalized fashion to the individual.
Global Awards and Recognitions
Within its short existence, LifeNome has won a significant number of global awards and recognitions for its personalization technologies.
• Global winner Zurich World Innovation Championship (2019)
• Finalist in NVIDIA Inception Accelerator (2018)
• Johnson and Johnson Quickfire (2018)
• COTY Incubator Awards (2018)
• Ranked Top Health DNA Company (DNA Testing Choice, 2017)
• Top 10 AI Companies in Health (Disruptor Daily 2017)
• Top 3 AI Companies (out of 135) (Bosch Venture Forum, 2017)
• Top 10 Genomics Solutions Providers (PharmaTech 2017)
• The key player in Genomics 2.0 (UBS, 2016)